Hoth Therapeutics Inc (HOTH)

NASDAQ
0.7799
+0.0419(+5.68%)
After Hours
0.8000
+0.0201(+2.5773%)
- Real-time Data
  • Volume:
    195,629
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    0.7100 - 0.7910

HOTH Overview

Prev. Close
0.738
Day's Range
0.71-0.791
Revenue
-
Open
0.7349
52 wk Range
0.69-3.49
EPS
-0.57
Volume
195,629
Market Cap
18.7M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
258,713
P/E Ratio
-
Beta
-
1-Year Change
-53.85%
Shares Outstanding
23,974,178
Next Earnings Date
Mar 02, 2022
What is your sentiment on Hoth Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Hoth Therapeutics Inc Company Profile

Employees
4

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellStrong Sell
Technical IndicatorsNeutralStrong BuyStrong BuyStrong SellStrong Sell
SummaryBuyStrong BuyBuyStrong SellStrong Sell
  • 🚀🚀🚀
    0
    • Buy, TP 5-6
      1
      • Jan 28, 2021, 08:02 ET Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic
        1
        • u're also here?
          0
      • Hoth Therapeutics Announces Production of HT-001 for Cancer TreatmentThu, December 31, 2020, 8:01 AM EST·4 min readHOTH+44.51%NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
        0
        • Long downfall/ stagnation then sudden activity indicates likely surge in growth for a term. News also indicates a keeper (look into partnerships).
          2
          • Long downfall/ stagnation then sudden activity indicates likely surge in growth for a term. News also indicates a keeper (look into partnerships).
            0
            • Wow! Anyone know the reason behind this surge? Cheers.
              0
              • Covid-19 precention halovax agreement with voltron.
                1
            • Wait again for it
              0
              • finally
                0
                • ?
                  0
                • 👍🏻 of 👎🏻
                  1
              • stock has good news...must move higher...
                1
                • in at 5.97
                  1
                  • in at 5.97
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.